TB R&D Weekly Update: TB Vaccine Efficacy Trial Yields Key Insights and Poor Results

The results of the first TB vaccine efficacy trial in over 90 years was released today showing that the vaccine candidate MVA85A when given as a booster did not provide added protection to infants who had already received BCG. The trial adds scientific value to the field and enhances the field’s understanding and ability in conducting large-scale TB vaccine trials.

Aeras and its partners will be hosting a teleconference to discuss the results and implications on February 6 at 8:30 a.m. EST. Click here for meeting invitation.

Lancet Article “Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial”–click here.

Lancet Commentary “A major event for new tuberculosis vaccines”–click here.

Additional Coverage:

First TB Vaccine Efficacy Study in Almost a Century Provides Key Insights: Vaccine Safe but Does Not Confer Protection, Calls for Redoubling Efforts on Global TB Vaccine Portfolio (Aeras)

Tuberculosis vaccine hopes dashed (BBC)

As Tuberculosis Vaccines Flounder, Developing Nations Join To Fight Drug-Resistant Diseases

Additional R&D News:

Tuberculosis Immunotherapy Grant for Immunoxel Honibe Honey Lozenges

New Drug for an Age-Old Disease

Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis [Review article]. (Int J Tuberc Lung Dis, Feb 2013)

Forsyth scientists gain new understanding of latent tuberculosis

The Tres Cantos Open Lab Foundation and Weill Cornell Medical College Join Forces on Tuberculosis Drug Discovery

Diospyrin inactivates a drug target for tuberculosis in new way

Can (MICs) governments make the global R&D system work for all?

More News
3 Aug 2023
The Working Group on New TB Drugs, in collaboration with the New Diagnostics Working Group, Working Group on New Vaccines, FIND, IAVI, and TB Alliance, is co-hosting a New Tools Summit at the Marriot Champs Elysée Hotel in Paris, France on Tuesday, 14 November 2023. The WGND Annual Meeting will be...
23 Aug 2022
The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-...
4 May 2022
Earlier this week, the World Health Organization (WHO) released a rapid communication which detailed the upcoming changes to the treatment guidance for drug-resistant tuberculosis (DR-TB). These guidelines are used to inform national TB programmes globally on how to treat patients with these...